Skip to main content

Table 2 Effect modification on hHF between dapagliflozin and empagliflozin by history of established ASCVD

From: Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease

 

Dapagliflozin

Empagliflozin

Dapagliflozin vs. empagliflozin

within the strata of ASCVD (+) and ASCVD (−)

ASCVD (+)

1.12 (0.87–1.45)

1 (reference)

1.12 (0.87–1.45)

ASCVD (-)

0.21 (0.15–0.28)

0.31 (0.24–0.40)

0.67 (0.49–0.90)

ASCVD (+) vs. ASCVD (−) within the strata of dapagliflozin and empagliflozin

5.47 (4.08–7.33)

3.24 (2.48–4.23)

 
  1. *Test for interaction: 0.0097
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840